<DOC>
	<DOCNO>NCT00224822</DOCNO>
	<brief_summary>The primary goal study assess effect aripiprazole patient develop metabolic syndrome take second generation antipsychotic medication .</brief_summary>
	<brief_title>The Effects Aripiprazole Patients With Metabolic Syndrome</brief_title>
	<detailed_description>Schizophrenia , schizoaffective disorder bipolar disorder severe disable disorder , associate mark social occupational dysfunction , tenfold suicidal risk , intensive healthcare resource utilization poor prognosis . Atypical antipsychotic develop last decade prove beneficial subset patient . These agent share reduce risk EPS tardive dyskinesia comparison first generation antipsychotic . They also appear improve negative , cognitive , depressive symptom least efficacious first generation `` typical '' drug control positive symptom schizophrenia schizoaffective disorder . Unfortunately , late 1990 's , case report study begin document number adverse event associate use second generation antipsychotic weight gain , hyperlipidemia hyperglycemia subsume name `` metabolic syndrome '' . Aripiprazole unique pharmacological mechanism , make drug ideal medication treatment patient experience metabolic syndrome second generation antipsychotic . In numerous pervious trial , demonstrate aripiprazole safe effective treatment schizophrenia , schizoaffective disorder bipolar disorder may actually reduce plasma glucose level improve lipid profile , lower risk cardiovascular disease /or diabetes . Thirty patient Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSM-IV ) diagnosis schizophrenia , schizoaffective disorder bipolar disorder experience 10 pound increase weight second generation antipsychotic hyperlipidemia , hyperglycemia , switch aripiprazole monitor improvement BMI , lipid glucose .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Males female DSMIV diagnosis schizophrenia , schizoaffective disorder , bipolar disorder , base chart review , develop significant weight gain clinically significant aspect metabolic syndrome include weight gain , hyperglycemia , diabetes , hyperlipidemia , second generation antipsychotic medication . Between 1865 year age Decisional capacity adequate provide inform consent authorize appropriate surrogate decision maker . If female , must agree use medically approve contraceptive posse potential bear child History adverse reaction aripiprazole Serious hepatic , renal , cardiac , neurological , pulmonary disease would prevent safe participation drug trial A diagnosis active drug alcohol abuse accord DSMIV criterion within last 30 day Suicidal homicidal ideation psychotic decompensation Patients Paxil , Remeron , tricyclic monoamine oxidase inhibitor ( MAOI ) antidepressant mood stabilizer lamotrigine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Psychiatry</keyword>
	<keyword>Antipsychotic</keyword>
	<keyword>Psychopharmacology</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Open Label</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizoaffective Disorder</keyword>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Metabolic Syndrome</keyword>
</DOC>